Response to inhaled ceftazidime in patients with non‐cystic fibrosis bronchiectasis and chronic bronchial infection unrelated to Pseudomonas aeruginosa

• Published in: The clinical respiratory journal 2022-11, Vol.16 (11), p.768-773
• Main Authors: Riveiro, Vanessa, Casal, Ana, Álvarez‐Dobaño, José M., Lourido, Tamara, Suárez‐Artime, Pedro, Rodríguez‐García, Carlota, Ferreiro, Lucía, Toubes, María E., Valdés, Luis
• Format: Article
• Language: English
• Subjects: Brief Report; Bronchitis; chronic bronchial infection unrelated to PA; Drug therapy; Infections; inhaled ceftazidime; non‐cystic fibrosis bronchiectasis; Respiratory system
• ISSN: 1752-6981; 1752-699X
• DOI: 10.1111/crj.13534

Introduction Inhaled antibiotics reduce the frequency of exacerbations. The objective was to assess the efficacy of inhaled ceftazidime in patients with non‐cystic fibrosis bronchiectasis (NCFB) and concomitant chronic bronchial infection (CBI) caused by potentially pathogenic microorganisms (PPM) other than Pseudomonas aeruginosa (PA). Material and Method Quasi‐experimental study in 21 patients with exacerbations who developed CBI by a PPM other than PA. Results Bacterial infection was resolved in 85.7% patients. Rehospitalizations, length of hospital stay, moderate exacerbations and blood levels of CRP decreased significantly. In addition, SGRQ questionnaire also decreased more than 4 points in 57.1% of the patients. Conclusion The results suggest that inhaled ceftazidime in NCFB unrelated to PA is a plausible alternative to the standard therapies used in clinical practice. Inhaled ceftazidime in patients with non‐cystic fibrosis bronchiectasis and concomitant chronic bronchial infection caused by potentially pathogenic microorganisms other than Pseudomonas aeruginosa reduce bacterial infection, rehospitalizations, length of hospital stay, moderate exacerbations, and blood levels of CRP decreased significantly. In addition, SGRQ questionnaire also decreased more than 4 points in 57.1% of the patients.